LGALS3 and cancer: These chemically-modified heparin derivatives, which show no detectable anti-coagulant activity and cytotoxicity, bind to galectin-3 carbohydrate recognition domain (CRD) and inhibit galectin-3-mediated cancer cell adhesion and angiogenesis in vitro and metastasis in vivo in a mouse model.